ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PTCHF Puretech Health PLC (PK)

2.26
-0.02 (-0.88%)
03 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Puretech Health PLC (PK) USOTC:PTCHF OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.02 -0.88% 2.26 2.20 2.35 2.35 2.225 2.225 3,159 17:20:23

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

11/10/2022 12:06pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October, 2022

Commission File Number 001-39670

 

 

PURETECH HEALTH PLC

(Translation of registrant’s name into English)

 

 

6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On October 11, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) and Nektar Therapeutics, Inc. (“Nektar”) each issued a press release, in accordance with the UK City Code on Takeovers and Mergers, regarding the mutual termination of discussions related to a possible business combination.

The press release issued by the Company is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. The press release issued by Nektar is furnished herewith as Exhibit 99.2 and is incorporated by reference herein.

Exhibits

 

99.1    Press Release of PureTech Health plc, dated October 11, 2022, titled “Statement regarding termination of discussions with Nektar Therapeutics (“Nektar”).”
99.2   

Press Release of Nektar Therapeutics, Inc., dated October 11, 2022, titled “Rule 2.8 Announcement.”

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  PURETECH HEALTH PLC
Date: October 11, 2022   By:  

/s/ Daphne Zohar

    Name:   Daphne Zohar
    Title:   Chief Executive Officer

1 Year Puretech Health (PK) Chart

1 Year Puretech Health (PK) Chart

1 Month Puretech Health (PK) Chart

1 Month Puretech Health (PK) Chart

Your Recent History

Delayed Upgrade Clock